IBDEI1BM ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,21352,2)
 ;;=^5003026
 ;;^UTILITY(U,$J,358.3,21353,0)
 ;;=E11.9^^70^914^11
 ;;^UTILITY(U,$J,358.3,21353,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21353,1,3,0)
 ;;=3^DM Type 2 w/o Complications
 ;;^UTILITY(U,$J,358.3,21353,1,4,0)
 ;;=4^E11.9
 ;;^UTILITY(U,$J,358.3,21353,2)
 ;;=^5002666
 ;;^UTILITY(U,$J,358.3,21354,0)
 ;;=E10.9^^70^914^1
 ;;^UTILITY(U,$J,358.3,21354,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21354,1,3,0)
 ;;=3^DM Type 1 w/o Complications
 ;;^UTILITY(U,$J,358.3,21354,1,4,0)
 ;;=4^E10.9
 ;;^UTILITY(U,$J,358.3,21354,2)
 ;;=^5002626
 ;;^UTILITY(U,$J,358.3,21355,0)
 ;;=Z79.4^^70^914^14
 ;;^UTILITY(U,$J,358.3,21355,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21355,1,3,0)
 ;;=3^Long Term Use of Insulin
 ;;^UTILITY(U,$J,358.3,21355,1,4,0)
 ;;=4^Z79.4
 ;;^UTILITY(U,$J,358.3,21355,2)
 ;;=^5063334
 ;;^UTILITY(U,$J,358.3,21356,0)
 ;;=E11.22^^70^914^3
 ;;^UTILITY(U,$J,358.3,21356,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21356,1,3,0)
 ;;=3^DM Type 2 w/ CKD
 ;;^UTILITY(U,$J,358.3,21356,1,4,0)
 ;;=4^E11.22
 ;;^UTILITY(U,$J,358.3,21356,2)
 ;;=^5002630
 ;;^UTILITY(U,$J,358.3,21357,0)
 ;;=E11.42^^70^914^10
 ;;^UTILITY(U,$J,358.3,21357,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21357,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Neuropathy
 ;;^UTILITY(U,$J,358.3,21357,1,4,0)
 ;;=4^E11.42
 ;;^UTILITY(U,$J,358.3,21357,2)
 ;;=^5002646
 ;;^UTILITY(U,$J,358.3,21358,0)
 ;;=E11.43^^70^914^2
 ;;^UTILITY(U,$J,358.3,21358,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21358,1,3,0)
 ;;=3^DM Type 2 w/ Autonomic Neuropathy
 ;;^UTILITY(U,$J,358.3,21358,1,4,0)
 ;;=4^E11.43
 ;;^UTILITY(U,$J,358.3,21358,2)
 ;;=^5002647
 ;;^UTILITY(U,$J,358.3,21359,0)
 ;;=E11.51^^70^914^9
 ;;^UTILITY(U,$J,358.3,21359,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21359,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/o Gangrene
 ;;^UTILITY(U,$J,358.3,21359,1,4,0)
 ;;=4^E11.51
 ;;^UTILITY(U,$J,358.3,21359,2)
 ;;=^5002650
 ;;^UTILITY(U,$J,358.3,21360,0)
 ;;=E11.52^^70^914^8
 ;;^UTILITY(U,$J,358.3,21360,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21360,1,3,0)
 ;;=3^DM Type 2 w/ Peripheral Angiopathy w/ Gangrene
 ;;^UTILITY(U,$J,358.3,21360,1,4,0)
 ;;=4^E11.52
 ;;^UTILITY(U,$J,358.3,21360,2)
 ;;=^5002651
 ;;^UTILITY(U,$J,358.3,21361,0)
 ;;=E11.621^^70^914^4
 ;;^UTILITY(U,$J,358.3,21361,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21361,1,3,0)
 ;;=3^DM Type 2 w/ Foot Ulcer
 ;;^UTILITY(U,$J,358.3,21361,1,4,0)
 ;;=4^E11.621
 ;;^UTILITY(U,$J,358.3,21361,2)
 ;;=^5002656
 ;;^UTILITY(U,$J,358.3,21362,0)
 ;;=E11.649^^70^914^6
 ;;^UTILITY(U,$J,358.3,21362,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21362,1,3,0)
 ;;=3^DM Type 2 w/ Hypoglycemia w/o Coma
 ;;^UTILITY(U,$J,358.3,21362,1,4,0)
 ;;=4^E11.649
 ;;^UTILITY(U,$J,358.3,21362,2)
 ;;=^5002662
 ;;^UTILITY(U,$J,358.3,21363,0)
 ;;=E11.65^^70^914^5
 ;;^UTILITY(U,$J,358.3,21363,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21363,1,3,0)
 ;;=3^DM Type 2 w/ Hyperglycemia
 ;;^UTILITY(U,$J,358.3,21363,1,4,0)
 ;;=4^E11.65
 ;;^UTILITY(U,$J,358.3,21363,2)
 ;;=^5002663
 ;;^UTILITY(U,$J,358.3,21364,0)
 ;;=E11.69^^70^914^7
 ;;^UTILITY(U,$J,358.3,21364,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,21364,1,3,0)
 ;;=3^DM Type 2 w/ Other Complications
 ;;^UTILITY(U,$J,358.3,21364,1,4,0)
 ;;=4^E11.69
 ;;^UTILITY(U,$J,358.3,21364,2)
 ;;=^5002664
 ;;^UTILITY(U,$J,358.3,21365,0)
 ;;=Z79.84^^70^914^13
